Comparative Effectiveness of Dexamethasone in Treatment of Hospitalized COVID-19 Patients during the First Year of the Pandemic: The N3C Data Repository

BACKGROUND: Dexamethasone, a widely available glucocorticoid, was approved for use in hospitalized COVID-19 patients early in the pandemic based on the RECOVERY trial; however, evidence is still needed to support its real-world effectiveness in patients with a wide range of comorbidities and in dive...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Richard, Johnson, Kaitlyn E., Rousseau, Justin F., Rathouz, Paul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628188/
https://www.ncbi.nlm.nih.gov/pubmed/36324806
http://dx.doi.org/10.1101/2022.10.22.22281373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628188/
https://www.ncbi.nlm.nih.gov/pubmed/36324806
http://dx.doi.org/10.1101/2022.10.22.22281373

Ejemplares similares